SymBio Pharmaceuticals Limited
SymBio Pharmaceuticals Limited
Your view on SYMQY
Overview
What the company does, where it operates, and who runs it.
About SymBio Pharmaceuticals Limited
- Industry
- Medical - Pharmaceuticals
- Sector
- Healthcare
- CEO
- Fuminori Yoshida
- Headquarters
- Toranomon 30 Mori Building, Tokyo, JP
- Industry
- Medical - Pharmaceuticals
- Sector
- Healthcare
- CEO
- Fuminori Yoshida
- Headquarters
- Toranomon 30 Mori Building, Tokyo, JP
SymBio Pharmaceuticals Limited engages in the research and development, manufacturing, and marketing of pharmaceutical drugs in the areas of oncology and hematology in Japan.
It is involved in the development of Treakisym SyB L-0501, an anti-cancer agent, which is marketed for the treatment of non-Hodgkin's lymphoma, multiple myeloma, and chronic lymphocytic leukemia under the TREAKISYM name; and is in the Phase III clinical trial to treat relapsed/refractory diffuse large B-cell lymphoma.
The company also engages in the development of SyB L-1701, a ready-to-dilute formulation; and SyB L-1702, a rapid infusion liquid formulation.
In addition, it is involved in the development of SyB L-1101, an intravenous formulation, which is in Phase III clinical trial for the treatment of higher-risk myelodysplastic syndromes (HR-MDS); and SyB C-1101, an oral formulation that is in Phase II/III clinical trial in combination with Azacitidine to treat HR-MDS.
Further, it engages in the development of SyB V-1901, an antiviral drug for the treatment of infectious diseases. SymBio Pharmaceuticals Limited was incorporated in 2005 and is based in Tokyo, Japan.
Media
Infographics, videos, and posts covering the company.
Stock Data
Price chart, volume, and trading data.
Fair Value
What FRC thinks it is worth vs. the current price.
FRC's fair value estimate for SymBio Pharmaceuticals Limited, and the rating behind it. SYMQY last traded at $0.56; the estimate is read against that market price. FRC analysts run the firm's valuation model across the companies on this platform to estimate what each one is worth, rather than republishing a consensus average. Shows the current estimate, our rating, and when it was last revised. A free account covers 7 company valuations a month; a paid subscription is unlimited.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
Valuation, profitability, liquidity and leverage ratios for SymBio Pharmaceuticals Limited. Starting points for SymBio Pharmaceuticals Limited: EPS -$78.95, beta 0.11 — an Medical - Pharmaceuticals name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
Dividend history, yield and payout sustainability for SymBio Pharmaceuticals Limited. SymBio Pharmaceuticals Limited does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
Reported vs. expected earnings history for SymBio Pharmaceuticals Limited. Trailing twelve-month EPS for SymBio Pharmaceuticals Limited stands at -$78.95. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Financial Statements
Income statement, balance sheet, and cash flow statements.
Income statement, balance sheet and cash flow history for SymBio Pharmaceuticals Limited. SymBio Pharmaceuticals Limited has reported as a listed company since 2016. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
SymBio Pharmaceuticals Limited valued side by side against its closest peers. SymBio Pharmaceuticals Limited is measured against Medical - Pharmaceuticals peers within the Healthcare sector. Peer-relative multiples and operating metrics, so the valuation is read in the context of its own sector rather than in isolation.
Institutional Ownership
PremiumWhich funds and firms own the stock.
Which institutions hold SymBio Pharmaceuticals Limited, and how their positions are changing. At a $27.2M market value, institutional positions materially move SymBio Pharmaceuticals Limited's register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings. Included with FRC Premium.
Insider Trading
PremiumRecent buying and selling by company executives.
Buying and selling by SymBio Pharmaceuticals Limited executives and directors. Shares of SymBio Pharmaceuticals Limited have traded between $0.56 and $1.31 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned. Included with FRC Premium.
Senate Trading
PremiumU.S. Senator disclosures filed under the STOCK Act.
U.S. Senate disclosures naming SymBio Pharmaceuticals Limited. SymBio Pharmaceuticals Limited is a $27.2M Healthcare company. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely. Included with FRC Premium.
House Trading
PremiumU.S. Representative disclosures filed under the STOCK Act.
U.S. House of Representatives disclosures naming SymBio Pharmaceuticals Limited. Representatives' reported transactions in this security, shown next to the company's fundamentals. Included with FRC Premium.
News
Latest headlines and market coverage.
Latest headlines and company announcements for SymBio Pharmaceuticals Limited. Coverage tracks SymBio Pharmaceuticals Limited within Medical - Pharmaceuticals (Healthcare). Press releases and market coverage, newest first.